397 related articles for article (PubMed ID: 23108405)
21. Effect of stable inhibition of NRF2 on doxorubicin sensitivity in human ovarian carcinoma OV90 cells.
Manandhar S; Lee S; Kwak MK
Arch Pharm Res; 2010 May; 33(5):717-26. PubMed ID: 20512470
[TBL] [Abstract][Full Text] [Related]
22. Effect of the XIAP inhibitor Embelin on TRAIL-induced apoptosis of pancreatic cancer cells.
Mori T; Doi R; Kida A; Nagai K; Kami K; Ito D; Toyoda E; Kawaguchi Y; Uemoto S
J Surg Res; 2007 Oct; 142(2):281-6. PubMed ID: 17640673
[TBL] [Abstract][Full Text] [Related]
23. Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo.
Vogler M; Walczak H; Stadel D; Haas TL; Genze F; Jovanovic M; Gschwend JE; Simmet T; Debatin KM; Fulda S
Cancer Res; 2008 Oct; 68(19):7956-65. PubMed ID: 18829553
[TBL] [Abstract][Full Text] [Related]
24. Down-regulation of the nuclear factor-kappaB by lidamycin in association with inducing apoptosis in human pancreatic cancer cells and inhibiting xenograft growth.
Chen J; Ouyang ZG; Zhang SH; Zhen YS
Oncol Rep; 2007 Jun; 17(6):1445-51. PubMed ID: 17487403
[TBL] [Abstract][Full Text] [Related]
25. Nrf2 inhibition reverses resistance to GPX4 inhibitor-induced ferroptosis in head and neck cancer.
Shin D; Kim EH; Lee J; Roh JL
Free Radic Biol Med; 2018 Dec; 129():454-462. PubMed ID: 30339884
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of NO-induced β-cell death by novel NF-κB inhibitor (-)-DHMEQ via activation of Nrf2-ARE pathway.
Ogasawara A; Simizu S; Ito A; Kawai T; Saisho Y; Takei I; Umezawa K
Biochem Biophys Res Commun; 2013 Apr; 433(2):181-7. PubMed ID: 23454127
[TBL] [Abstract][Full Text] [Related]
27. Trigonelline inhibits Nrf2 via EGFR signalling pathway and augments efficacy of Cisplatin and Etoposide in NSCLC cells.
Fouzder C; Mukhuty A; Mukherjee S; Malick C; Kundu R
Toxicol In Vitro; 2021 Feb; 70():105038. PubMed ID: 33148531
[TBL] [Abstract][Full Text] [Related]
28. SC68896, a novel small molecule proteasome inhibitor, exerts antiglioma activity in vitro and in vivo.
Roth P; Kissel M; Herrmann C; Eisele G; Leban J; Weller M; Schmidt F
Clin Cancer Res; 2009 Nov; 15(21):6609-18. PubMed ID: 19825946
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of the ubiquitin-proteasome system sensitizes TRAIL-resistant prostate cancer cells by up-regulation of death receptor 5.
Lee YJ; Seol JW; Jeong JK; Moon MH; Park SY
Mol Med Rep; 2011; 4(6):1255-9. PubMed ID: 21850375
[TBL] [Abstract][Full Text] [Related]
30. Proteasome inhibition induces both antioxidant and hb f responses in sickle cell disease via the nrf2 pathway.
Pullarkat V; Meng Z; Tahara SM; Johnson CS; Kalra VK
Hemoglobin; 2014; 38(3):188-95. PubMed ID: 24670032
[TBL] [Abstract][Full Text] [Related]
31. Upregulation of DR5 by proteasome inhibitors potently sensitizes glioma cells to TRAIL-induced apoptosis.
Hetschko H; Voss V; Seifert V; Prehn JH; Kögel D
FEBS J; 2008 Apr; 275(8):1925-36. PubMed ID: 18341587
[TBL] [Abstract][Full Text] [Related]
32. Enhanced sensitivity of A549 cells to the cytotoxic action of anticancer drugs via suppression of Nrf2 by procyanidins from Cinnamomi Cortex extract.
Ohnuma T; Matsumoto T; Itoi A; Kawana A; Nishiyama T; Ogura K; Hiratsuka A
Biochem Biophys Res Commun; 2011 Oct; 413(4):623-9. PubMed ID: 21925486
[TBL] [Abstract][Full Text] [Related]
33. The antioxidant transcription factor Nrf2 modulates the stress response and phenotype of malignant as well as premalignant pancreatic ductal epithelial cells by inducing expression of the ATF3 splicing variant ΔZip2.
Kha ML; Hesse L; Deisinger F; Sipos B; Röcken C; Arlt A; Sebens S; Helm O; Schäfer H
Oncogene; 2019 Feb; 38(9):1461-1476. PubMed ID: 30302023
[TBL] [Abstract][Full Text] [Related]
34. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo.
Singh TR; Shankar S; Chen X; Asim M; Srivastava RK
Cancer Res; 2003 Sep; 63(17):5390-400. PubMed ID: 14500373
[TBL] [Abstract][Full Text] [Related]
35. Immediate early gene-X1 interferes with 26 S proteasome activity by attenuating expression of the 19 S proteasomal components S5a/Rpn10 and S1/Rpn2.
Arlt A; Minkenberg J; Kruse ML; Grohmann F; Fölsch UR; Schäfer H
Biochem J; 2007 Mar; 402(2):367-75. PubMed ID: 17107344
[TBL] [Abstract][Full Text] [Related]
36. Antitumor activity of a novel recombinant mutant human tumor necrosis factor-related apoptosis-inducing ligand.
Fang F; Wang AP; Yang SF
Acta Pharmacol Sin; 2005 Nov; 26(11):1373-81. PubMed ID: 16225761
[TBL] [Abstract][Full Text] [Related]
37. Radiation-inducible human tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene therapy: a novel treatment for radioresistant uveal melanoma.
Zhou Y; Song X; Jia R; Wang H; Dai L; Xu X; Gu P; Ge S; Fan X
Pigment Cell Melanoma Res; 2010 Oct; 23(5):661-74. PubMed ID: 20546535
[TBL] [Abstract][Full Text] [Related]
38. Drug-induced expression of the cellular adhesion molecule L1CAM confers anti-apoptotic protection and chemoresistance in pancreatic ductal adenocarcinoma cells.
Sebens Müerköster S; Werbing V; Sipos B; Debus MA; Witt M; Grossmann M; Leisner D; Kötteritzsch J; Kappes H; Klöppel G; Altevogt P; Fölsch UR; Schäfer H
Oncogene; 2007 Apr; 26(19):2759-68. PubMed ID: 17086212
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of RIP and c-FLIP enhances TRAIL-induced apoptosis in pancreatic cancer cells.
Wang P; Zhang J; Bellail A; Jiang W; Hugh J; Kneteman NM; Hao C
Cell Signal; 2007 Nov; 19(11):2237-46. PubMed ID: 17693058
[TBL] [Abstract][Full Text] [Related]
40. SKP2 confers resistance of pancreatic cancer cells towards TRAIL-induced apoptosis.
Schüler S; Diersch S; Hamacher R; Schmid RM; Saur D; Schneider G
Int J Oncol; 2011 Jan; 38(1):219-25. PubMed ID: 21109943
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
